Did China just fire shots at America?
Last week, in Tiananmen Square, China put on a chilling display of military power.
Fighter jets, tanks, AI-guided drones — all paraded under the red flag, in front of Vladimir Putin, Kim Jong Un, and more than two dozen world leaders.
Meanwhile, in Washington, President Trump watched.
“They were hoping I was watching,” he said. “And I was watching.”
But what he didn’t say matters more. Because while the media calls it a “celebration,” those of us paying attention know what it really was:
A warning shot at America. A not-so-subtle message to the United States — and to every American who still believes we call the shots.
The world is realigning. China. Russia. India. They’re drawing closer. And Trump’s high-risk trade policies are pushing them into each other’s arms.
The U.S. is becoming isolated and distrusted under our glorious leader.
And we’re drowning in debt – $21 billion a day added and growing.
And this Chinese parade – as symbolic as it was strategic – signals that the world may be entering a post-American financial era.
One where the dollar no longer dominates… and U.S. influence is no longer guaranteed.
The White House won’t admit it, but the signs are everywhere.
Foreign alliances are being formed without us… economic blocks are shifting against us… our tariffs are backfiring and capital is fleeing the country… debt is exploding past $37 trillion with no plans to stop it.
For those looking to protect themselves as this global power shift takes place… I highly suggest you watch this critical broadcast from Porter Stansberry.
In it, he details exactly how this new global power structure could impact your finances… and what he believes every American must do to protect their money before September 30, when America’s 2026 budget exposes just how bad things have become.
Biotech Breakouts: 3 Stocks With Massive Upside Potential
Written by Chris Markoch. Published 9/17/2025.
Key Points
- Viking stock is down, but still has major upside in the obesity drug market.
- ImmunityBio advances Anktiva beyond bladder cancer with new trial results.
- Maze Therapeutics rallies on early-stage data with more catalysts ahead.
Investing in biotechnology stocks can be complex, given the science behind drug candidates. These names are notoriously volatile, often swinging double digits in either direction.
Still, biotech stocks can offer a compelling long-term risk-reward profile. For investors with the patience to hold through the clinical trial phase, the potential payoffs in these three companies could be substantial.
Viking: An Obesity Challenger with Big Upside
Musk's Project Colossus could mint millionaires (Ad)
I predict this single breakthrough could make Elon the world's first trillionaire — and mint more new millionaires than any tech advance in history.
And for a limited time, you have the chance to claim a stake in this project, even though it's housed inside Elon's private company, xAI.
Viking Therapeutics Inc. (NASDAQ: VKTX) surged in 2024 alongside the GLP-1 weight-loss craze. In 2025, however, the stock has fallen over 40%, including a 20% drop after its August clinical trial update. The results were solid—patients averaged 12.2% weight loss—and Viking did not technically fail the trial.
Investors worried those losses came at the highest dosage, especially compared with competitors showing similar or better results at lower levels. A 28% dropout rate also raised concerns about potential side effects.
Does that justify a nearly 50% plunge? Analysts consider the reaction excessive, setting a consensus price target of $87.50, which implies roughly 270% upside from current levels.
With the obesity drug market large enough to support more than just Novo Nordisk and Eli Lilly, this could be an opportune moment for conviction investors to accumulate VKTX.
From a technical standpoint, VKTX appears to be bottoming. Its Relative Strength Index (RSI) is near 34—close to oversold territory—and the MACD hints at waning bearish momentum. After forming a death cross in late August, investors may look for a golden cross as an early sign of an uptrend.
ImmunityBio: A Penny Stock with Serious Potential
ImmunityBio Inc. (NASDAQ: IBRX) is up about 8.4% so far in 2025, with most gains coming in the past month. In late August, the company reported that all five patients in its glioblastoma pilot study "attained 100% disease control" using a regimen that includes its ANKTIVA drug.
ANKTIVA, approved by the FDA in April 2024 for bladder cancer, is now in trials for other cancers. The company is also exploring it as a potential treatment for HIV and Long COVID—making it one of the most exciting immunotherapy candidates in development.
Analysts peg IBRX's consensus price target at $10.75, implying over 280% upside. Short term, however, caution may be wise: IBRX trades above its 200-day moving average and carries an RSI of 76, a level that has historically served as resistance.
While investors might wait for a pullback before initiating positions, the long-term thesis remains intact. If ANKTIVA proves effective across multiple indications, IBRX could transition from penny-stock status to biotech heavyweight.
Maze Therapeutics: Early Success in Rare Diseases
Maze Therapeutics Inc. (NASDAQ: MAZE) began trading publicly in February 2025. Since then, the stock has climbed approximately 86%, and analysts see room for further gains.
On Sept. 11, Maze reported promising Phase 1 results for its lead candidate, MZE782. The data established proof of mechanism for a potent, oral SLC6A19 inhibitor targeting phenylketonuria (PKU) and chronic kidney disease (CKD), paving the way for a Phase 2 trial.
Approval remains years away, with no guarantee of success. Yet analysts remain optimistic—HC Wainwright is the most bullish, with a $50 price target, roughly double today's level.
Parabolic runs often warrant caution: MAZE's RSI nears overbought territory, though it recently found support around $22.40. Confirmation of that level would suggest bullish momentum.
MAZE offers exposure to rare-disease therapeutics—an area known for strong pricing power and lower competition. If clinical progress continues, the stock could sustain further gains.
This message is a sponsored email for Porter & Company, a third-party advertiser of The Early Bird and MarketBeat.
If you have questions about your account, feel free to email our South Dakota based support team at contact@marketbeat.com.
If you no longer wish to receive email from The Early Bird, you can unsubscribe.
© 2006-2025 MarketBeat Media, LLC.
345 N Reid Pl., Sixth Floor, Sioux Falls, SD 57103-7078. USA..